Sign Up Today and Learn More About Actio Biosciences Stock
Invest in or calculate the value of your shares in Actio Biosciences or other pre-IPO companies through EquityZen's platform.
Actio Biosciences Stock
Actio Biosciences is a research center that develops drugs for rare diseases.
About Actio Biosciences Stock
Founded
2021
Headquarters
San Diego, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Actio Biosciences Press Mentions
Stay in the know about the latest news on Actio Biosciences
Charcot-Marie-Tooth Disease Market Size to Hit USD 1,166.98Bn by 2033, Forecast & Growth Rate
einpresswire • Oct 28, 2025
Actio Biosciences Announces First Participant Dosed in Phase 1 Clinical Trial of ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
pharmiweb • Sep 23, 2025
CMT Research Foundation Provides Funding to Four Innovative Projects Through Emerging Researcher Award
einpresswire • Sep 12, 2025
Actio Biosciences to Participate in TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
pharmiweb • Sep 12, 2025
Actio Biosciences Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ABS-1230, a KCNT1 Inhibitor for the Treatment of KCNT1-Related Epilepsy
businesswire • Jul 30, 2025
Actio Biosciences Management
Leadership team at Actio Biosciences
Board Member
Jason Fuller
Board Member
Nina Kjellson
Join now and verify your accreditation status to gain access to:
- Actio Biosciences Current Valuation
- Actio Biosciences Stock Price
- Actio Biosciences Management
- Available deals in Actio Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Actio Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- Actio Biosciences Revenue and Financials
- Actio Biosciences Highlights
- Actio Biosciences Business Model
- Actio Biosciences Risk Factors
- Actio Biosciences Research Report from SACRA Research
Trading Actio Biosciences Stock
How to invest in Actio Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Actio Biosciences through EquityZen funds. These investments are made available by existing Actio Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Actio Biosciences stock?
Shareholders can sell their Actio Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 400K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 49K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."